Showing posts with label VEGF. Show all posts
Showing posts with label VEGF. Show all posts

Saturday, November 3, 2012

A new opportunity in ovarian cancer treatment


A new opportunity in ovarian cancer treatment


Fall 2012

[Article in Czech]

Abstract


Objective: Targeted treatment in ovarian cancer patients.

Design: Practical paper.Setting: Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

Conclusion: Targeted treatment is possible based on particular characteristics of single tumors in ovarian cancer patients. Better understanding of tumor biology should contribute to predict certain patients would benefit most from use of targeted treatment. Key words:ovarian cancer, VEGF, bevacizumab, targeted treatment.

Roche receives EC approval for treatment of platinum-sensitive ovarian cancer


Roche receives EC approval for treatment of platinum-sensitive ovarian cancer


Comtex News Network

Nov 02, 2012 (Datamonitor via COMTEX) -- Roche Holding AG has received European Commission, or EC, approval for Avastin in combination with standard chemotherapy, carboplatin and gemcitabine, as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.
Avastin is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. The additional approval of the medicine is important for women with ovarian cancer who are now able to receive Avastin in combination with chemotherapy once their disease returns.
Patients are said to have 'platinum-sensitive' disease if their ovarian cancer returns more than 6 months after completion of platinum-based chemotherapy.
This approval was based on data from the Phase III OCEANS study which showed that women with recurrent, platinum-sensitive ovarian cancer who received Avastin in combination with chemotherapy lived significantly longer without their disease getting worse (progression-free survival) compared to those who received chemotherapy alone (HR=0.48; p<0.0001).
Ovarian cancer is associated with high concentrations of vascular endothelial growth factor (VEGF), a protein associated with tumor growth and spread. Avastin is an antibody that precisely targets and inhibits VEGF for tumor control, the company said.
"This EU approval of Avastin is an important advance for women with recurrent ovarian cancer because very few treatment advances have been made in over a decade for patients with the disease," said Hal Barron, Roche's chief medical officer and head of global product development.
http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon 

Wednesday, October 24, 2012

Growth Differentiation Factor 15 Stimulates Rapamycin-Sensitive Ovarian Cancer Cell Growth and Invasion.


Growth Differentiation Factor 15 Stimulates Rapamycin-Sensitive Ovarian Cancer Cell Growth and Invasion.


Oct 2012

Source

Departments of Pharmacology; Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322; Departments of Winship Cancer Institute; Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322.

Abstract


Identification of novel molecular markers and therapeutic targets may improve survival rates for patients with ovarian cancer. In the current study, immunohistochemical (IHC) analysis of two human ovarian tumor tissue arrays showed high staining for GDF15 in a majority of tissues. Exogenous stimulation of ovarian cancer cell lines with recombinant human GDF15 (rhGDF15) or stable over-expression of a GDF15 expression plasmid promoted anchorage-independent growth, increased invasion, and up-regulation of matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF). MMP inhibition suppressed GDF15-mediated invasion. In addition, IHC analysis of human ovarian tumor tissue arrays indicated that GDF15 expression correlated significantly with high MMP2 and MMP9 expression. Exogenous and endogenous GDF15 over-expression stimulated phosphorylation of p38, Erk1/2, and Akt. Pharmacologic inhibition of p38, MEK, or PI3K suppressed GDF15-stimulated growth. Further, proliferation, growth, and invasion of GDF15 stable clones were blocked by rapamycin. IHC analysis demonstrated significant correlation between GDF15 expression and phosphorylation of mTOR. Finally, knockdown of endogenous GDF15 or neutralization of secreted GDF15 suppressed invasion and growth of a GDF15-over-expressing ovarian cancer cell line. These data indicate that GDF15 over-expression, which occurred in a majority of human ovarian cancers, promoted rapamycin-sensitive invasion and growth of ovarian cancer cells. Inhibition of mTOR may be an effective therapeutic strategy for ovarian cancers that over-express GDF15. Future studies should examine GDF15 as a novel molecular target for blocking ovarian cancer progression.